-
摘要: 前列腺癌(PCa)的治疗在过去十年取得了重要的进展。随着免疫疗法在肿瘤治疗领域的不断深入，PCa的治疗正在进入肿瘤免疫治疗时代。如今的PCa免疫疗法主要包括肿瘤疫苗、免疫检查位点抑制剂和CAR-T细胞疗法等。与此同时，免疫疗法与其他疗法如放射治疗、激素治疗等的联合应用也是研究的热点。近年来，基因检测技术的飞速发展也在指导免疫疗法不断改进。现如今的免疫治疗方法为PCa治疗带来了更多新的途径和希望，但在临床应用方面依然有限，未来需要更深入的基础研究与临床试验来完善。本文就近年来免疫疗法在PCa中运用的最新进展作一综述。Abstract: The treatment of prostate cancer (PCa) has made important progress in the past decade. With the continuous development of immunotherapy in the field of tumor treatment, the treatment of PCa is entering the era of tumor immunotherapy. Today's PCa immunotherapy mainly includes tumor vaccines, immune check site inhibitors, and CAR-T cell therapy. At the same time, the combined application of immunotherapy and other therapies such as radiotherapy and hormone therapy is also a research hotspot. In recent years, the rapid development of genetic testing technology is also guiding the continuous improvement of immunotherapy. Today's immunotherapy methods have brought more new approaches and hopes for the treatment of PCa, but their clinical applications are still limited. In the future, more in-depth basic research and clinical trials are needed to improve them. This article reviews the latest advances in the use of immunotherapy in PCa in recent years.
-
Key words:
- prostate carcinoma /
- immunotherapy /
- immune checkpoint inhibitors /
- tumor vaccine /
- CAR-T cell therapy
-
-
[1] Erratum: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2020, 70(4): 313.
[2] Dong L, Zieren RC, Xue W, et al. Metastatic prostate cancer remains incurable, why?[J]. Asian J Urol, 2019, 6(1): 26-41. doi: 10.1016/j.ajur.2018.11.005
[3] Swami U, McFarland TR, Nussenzveig R, et al. Advanced Prostate Cancer: Treatment Advances and Future Directions[J]. Trends Cancer, 2020, 6(8): 702-715. doi: 10.1016/j.trecan.2020.04.010
[4] Gao J, Ward JF, Pettaway CA, et al. VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer[J]. Nat Med, 2017, 23(5): 551-555. doi: 10.1038/nm.4308
[5] Melero I, Gomez-Roca C, Ferre P, et al. 315 W0180 novel anti-VISTA antibody: Rationale for target patient population and first-in-human trial design in monotherapy and in combination with anti-PD1 antibody[J]. Journal for Immuno Therapy of Cancer, 2020, 8(Suppl 3): 341-343.
[6] Antonarakis ES, Piulats JM, Gross-Goupil M, et al. Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase Ⅱ KEYNOTE-199 Study[J]. J Clin Oncol, 2020, 38(5): 395-405. doi: 10.1200/JCO.19.01638
[7] Hansen AR, Massard C, Ott PA, et al. Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study[J]. Ann Oncol, 2018, 29(8): 1807-1813. doi: 10.1093/annonc/mdy232
[8] Fiegle E, Doleschel D, Koletnik S, et al. Dual CTLA-4 and PD-L1 Blockade Inhibits Tumor Growth and Liver Metastasis in a Highly Aggressive Orthotopic Mouse Model of Colon Cancer[J]. Neoplasia, 2019, 21(9): 932-944. doi: 10.1016/j.neo.2019.07.006
[9] Hannani D, Vétizou M, Enot D, et al. Erratum: anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25[J]. Cell Res, 2015, 25(3): 399-400. doi: 10.1038/cr.2015.28
[10] Kwon ED, Drake CG, Scher HI, et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy(CA184-043): a multicentre, randomised, double-blind, phase 3 trial[J]. Lancet Oncol, 2014, 15(7): 700-712. doi: 10.1016/S1470-2045(14)70189-5
[11] Beer TM, Kwon ED, Drake CG, et al. Randomized, Double-Blind, Phase Ⅲ Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer[J]. J Clin Oncol, 2017, 35(1): 40-47. doi: 10.1200/JCO.2016.69.1584
[12] Sinha M, Zhang L, Subudhi S, et al. Pre-existing immune status associated with response to combination of sipuleucel-T and ipilimumab in patients with metastatic castration-resistant prostate cancer[J]. J Immunother Cancer, 2021, 9(5): 51-72.
[13] Cha HR, Lee JH, Ponnazhagan S. Revisiting Immunotherapy: A Focus on Prostate Cancer[J]. Cancer Res, 2020, 80(8): 1615-1623. doi: 10.1158/0008-5472.CAN-19-2948
[14] Benzon B, Glavaris SA, Simons BW, et al. Combining immune check-point blockade and cryoablation in an immunocompetent hormone sensitive murine model of prostate cancer[J]. Prostate Cancer Prostatic Dis, 2018, 21(1): 126-136. doi: 10.1038/s41391-018-0035-z
[15] Witt K, Evans-Axelsson S, Lundqvist A, et al. Inhibition of STAT3 augments antitumor efficacy of anti-CTLA-4 treatment against prostate cancer[J]. Cancer Immunol Immunother, 2021, 70(11): 3155-3166. doi: 10.1007/s00262-021-02915-6
[16] Sharma P, Pachynski R, Narayan V, et al. Initial results from a phase Ⅱ study of nivolumab(NIVO)plus ipilimumab(IPI)for the treatment of metastatic castration-resistant prostate cancer(mCRPC; CheckMate 650)[J]. J Clini Oncol, 2019, 37(7_suppl): 142-142. doi: 10.1200/JCO.2019.37.7_suppl.142
[17] Anti-PD-1-CTLA4 Combo Hits Prostate Cancer[J]. Cancer Discov, 2019, 9(5): 569-570.
[18] Lin YX, Wang Y, Ding J, et al. Reactivation of the tumor suppressor PTEN by mRNA nanoparticles enhances antitumor immunity in preclinical models[J]. Sci Transl Med, 2021, 13(599): 599-615.
[19] Madan RA, Antonarakis ES, Drake CG, et al. Putting the Pieces Together: Completing the Mechanism of Action Jigsaw for Sipuleucel-T[J]. J Natl Cancer Inst, 2020, 112(6): 562-573. doi: 10.1093/jnci/djaa021
[20] Zhang L, Kandadi H, Yang H, et al. Long-term Sculpting of the B-cell Repertoire following Cancer Immunotherapy in Patients Treated with Sipuleucel-T[J]. Cancer Immunol Res, 2020, 8(12): 1496-1507. doi: 10.1158/2326-6066.CIR-20-0252
[21] Gulley JL, Borre M, Vogelzang NJ, et al. Phase Ⅲ Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer[J]. J Clin Oncol, 2019, 37(13): 1051-1061. doi: 10.1200/JCO.18.02031
[22] Abdul Sater H, Marté JL, Donahue RN, et al. Neoadjuvant PROSTVAC prior to radical prostatectomy enhances T-cell infiltration into the tumor immune microenvironment in men with prostate cancer[J]. J Immunother Cancer, 2020, 8(1): 655-664.
[23] Kimura T, Egawa S, Uemura H. Personalized peptide vaccines and their relation to other therapies in urological cancer[J]. Nat Rev Urol, 2017, 14(8): 501-510. doi: 10.1038/nrurol.2017.77
[24] Higano CS, Corman JM, Smith DC, et al. Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer[J]. Cancer, 2008, 113(5): 975-984. doi: 10.1002/cncr.23669
[25] Higano C, Saad F, Somer B. A phase Ⅲ trial of GVAX immunotherapy for prostate cancer versus docetaxel plus prednisone in asymptomatic, castration-resistant prostate cancer(CRPC)[J]. J Clin Oncol, 2009, 27(Suppl 15S): 26-28.
[26] Noguchi M, Arai G, Egawa S, et al. Mixed 20-peptide cancer vaccine in combination with docetaxel and dexamethasone for castration-resistant prostate cancer: a randomized phase Ⅱ trial[J]. Cancer Immunol Immunother, 2020, 69(5): 847-857. doi: 10.1007/s00262-020-02498-8
[27] Simons BW, Cannella F, Rowley DT, et al. Bovine papillomavirus prostate cancer antigen virus-like particle vaccines are efficacious in advanced cancers in the TRAMP mouse spontaneous prostate cancer model[J]. Cancer Immunol Immunother, 2020, 69(4): 641-651. doi: 10.1007/s00262-020-02493-z
[28] Shi X, Sun J, Li H, et al. Antitumor efficacy of interferon-γ-modified exosomal vaccine in prostate cancer[J]. Prostate, 2020, 80(11): 811-823. . doi: 10.1002/pros.23996
[29] McNeel DG, Eickhoff JC, Johnson LE, et al. Phase Ⅱ Trial of a DNA Vaccine Encoding Prostatic Acid Phosphatase(pTVG-HP[MVI-816])in Patients With Progressive, Nonmetastatic, Castration-Sensitive Prostate Cancer[J]. J Clin Oncol, 2019, 37(36): 3507-3517. doi: 10.1200/JCO.19.01701
[30] Fang Y, Mo F, Shou J, et al. A Pan-cancer Clinical Study of Personalized Neoantigen Vaccine Monotherapy in Treating Patients with Various Types of Advanced Solid Tumors[J]. Clin Cancer Res, 2020, 26(17): 4511-4520. doi: 10.1158/1078-0432.CCR-19-2881
[31] McKay RR, Hafron JM, Ferro C, et al. A Retrospective Observational Analysis of Overall Survival with Sipuleucel-T in Medicare Beneficiaries Treated for Advanced Prostate Cancer[J]. Adv Ther, 2020, 37(12): 4910-4929. doi: 10.1007/s12325-020-01509-5
[32] Obradovic AZ, Dallos MC, Zahurak ML, et al. T-Cell Infiltration and Adaptive Treg Resistance in Response to Androgen Deprivation With or Without Vaccination in Localized Prostate Cancer[J]. Clin Cancer Res, 2020, 26(13): 3182-3192. doi: 10.1158/1078-0432.CCR-19-3372
[33] Marshall CH, FU W, Wang H, et al. Randomized Phase Ⅱ Trial of Sipuleucel-T with or without Radium-223 in Men with Bone-metastatic Castration-resistant Prostate Cancer[J]. Clin Cancer Res, 2021, 27(6): 1623-1630. doi: 10.1158/1078-0432.CCR-20-4476
[34] Sternberg C, Armstrong A, Pili R, et al. Randomized, Double-Blind, Placebo-Controlled Phase Ⅲ Study of Tasquinimod in Men With Metastatic Castration-Resistant Prostate Cancer[J]. J Clin Oncol, 2016, 34(22): 2636-2643. doi: 10.1200/JCO.2016.66.9697
[35] Fizazi K, Ulys A, Sengeløv L, et al. A randomized, double-blind, placebo-controlled phase Ⅱ study of maintenance therapy with tasquinimod in patients with metastatic castration-resistant prostate cancer responsive to or stabilized during first-line docetaxel chemotherapy[J]. Ann Oncol, 2017, 28(11): 2741-2746. doi: 10.1093/annonc/mdx487
[36] Sanaei MJ, Taheri F, Heshmati M, et al. Comparing the frequency of CD33+ pSTAT3+ myeloid-derived suppressor cells and IL-17+ lymphocytes in patients with prostate cancer and benign prostatic hyperplasia[J]. Cell Biol Int, 2021, 45(10): 2086-2095. doi: 10.1002/cbin.11651
[37] Dong L, Myers KV, Pienta KJ. Understanding the tumor-immune microenvironment in prostate cancer[J]. Curr Opin Oncol, 2021, 33(3): 231-237. doi: 10.1097/CCO.0000000000000719
[38] Don-Doncow N, Escobar Z, Johansson M, et al. Galiellalactone is a direct inhibitor of the transcription factor STAT3 in prostate cancer cells[J]. J Biol Chem, 2014, 289(23): 15969-71598. doi: 10.1074/jbc.M114.564252
[39] Canesin G, Evans-Axelsson S, Hellsten R, et al. The STAT3 Inhibitor Galiellalactone Effectively Reduces Tumor Growth and Metastatic Spread in an Orthotopic Xenograft Mouse Model of Prostate Cancer[J]. Eur Urol, 2016, 69(3): 400-404. doi: 10.1016/j.eururo.2015.06.016
[40] Hellsten R, Lilljebjörn L, Johansson M, et al. The STAT3 inhibitor galiellalactone inhibits the generation of MDSC-like monocytes by prostate cancer cells and decreases immunosuppressive and tumorigenic factors[J]. Prostate, 2019, 79(14): 1611-1621. doi: 10.1002/pros.23885
[41] Sadelain M, Rivière I, Riddell S. Therapeutic T cell engineering[J]. Nature, 2017, 545(7655): 423-431. doi: 10.1038/nature22395
[42] Junghans RP, Ma Q, Rathore R, et al. Phase Ⅰ Trial of Anti-PSMA Designer CAR-T Cells in Prostate Cancer: Possible Role for Interacting Interleukin 2-T Cell Pharmacodynamics as a Determinant of Clinical Response[J]. Prostate, 2016, 76(14): 1257-1270. doi: 10.1002/pros.23214
[43] Slovin SF, Wang XY, Hullings M, et al. Chimeric antigen receptor(CAR+)modified T cells targeting prostate-specific membrane antigen(PSMA)in patients(pts)with castrate metastatic prostate cancer(CMPC)[J]. J Clin Oncol, 2013, 31(6): 2536-2536.
[44] Ma Q, Gomes EM, Lo AS, et al. Advanced generation anti-prostate specific membrane antigen designer T cells for prostate cancer immunotherapy[J]. Prostate, 2014, 74(3): 286-296. doi: 10.1002/pros.22749
[45] Hassani M, Hajari Taheri F, Sharifzadeh Z, et al. Construction of a chimeric antigen receptor bearing a nanobody against prostate a specific membrane antigen in prostate cancer[J]. J Cell Biochem, 2019, 120(6): 10787-10795. doi: 10.1002/jcb.28370
[46] Foster AE, Mahendravada A, Shinners NP, et al. Regulated Expansion and Survival of Chimeric Antigen Receptor-Modified T Cells Using Small Molecule-Dependent Inducible MyD88/CD40[J]. Mol Ther, 2017, 25(9): 2176-2188. doi: 10.1016/j.ymthe.2017.06.014
[47] Becerra RC, Hoof P, Paulson AS, et al. Ligand-inducible, prostate stem cell antigen(PSCA)-directed GoCAR-T cells in advanced solid tumors: Preliminary results from a dose escalation[J]. J Clin Oncol, 2019, 37(4_suppl): 283-285. doi: 10.1200/JCO.2019.37.4_suppl.283
[48] Han J, Gao F, Geng S, et al. Minicircle DNA-Engineered CAR T Cells Suppressed Tumor Growth in Mice[J]. Mol Cancer Ther, 2020, 19(1): 178-186. doi: 10.1158/1535-7163.MCT-19-0204
[49] Yang G, Zheng RY, Jin ZS. Correlations between microsatellite instability and the biological behaviour of tumours[J]. J Cancer Res Clin Oncol, 2019, 145(12): 2891-2899. doi: 10.1007/s00432-019-03053-4
[50] Luchini C, Bibeau F, Ligtenberg M, et al. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach[J]. Ann Oncol, 2019, 30(8): 1232-1243. doi: 10.1093/annonc/mdz116
[51] Huang R, Haberberger J, Severson E, et al. A pan-cancer analysis of PD-L1 immunohistochemistry and gene amplification, tumor mutation burden and microsatellite instability in 48, 782 cases[J]. Mod Pathol, 2021, 34(2): 252-263. doi: 10.1038/s41379-020-00664-y
[52] Marcus L, Lemery SJ, Keegan P, et al. FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors[J]. Clin Cancer Res, 2019, 25(13): 3753-3758. doi: 10.1158/1078-0432.CCR-18-4070
[53] Abida W, Cheng ML, Armenia J, et al. Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade[J]. JAMA Oncol, 2019, 5(4): 471-478. doi: 10.1001/jamaoncol.2018.5801
[54] Tucker MD, Zhu J, Marin D, et al. Pembrolizumab in men with heavily treated metastatic castrate-resistant prostate cancer[J]. Cancer Med, 2019, 8(10): 4644-4655. doi: 10.1002/cam4.2375
[55] Subudhi SK, Vence L, Zhao H, et al. Neoantigen responses, immune correlates, and favorable outcomes after ipilimumab treatment of patients with prostate cancer[J]. Sci Transl Med, 2020, 12(537): 3577-3588. doi: 10.1126/scitranslmed.aaz3577
[56] Sun J, Li S, Wang F, et al. Identification of key pathways and genes in PTEN mutation prostate cancer by bioinformatics analysis[J]. BMC Med Genet, 2019, 20(1): 191. doi: 10.1186/s12881-019-0923-7
[57] Peng W, Chen JQ, Liu C, et al. Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy[J]. Cancer Discov, 2016, 6(2): 202-216. doi: 10.1158/2159-8290.CD-15-0283
[58] Rescigno P, Gurel B, Pereira R, et al. Characterizing CDK12-Mutated Prostate Cancers[J]. Clin Cancer Res, 2021, 27(2): 566-574. doi: 10.1158/1078-0432.CCR-20-2371
[59] Kast F, Klein C, Umaña P, et al. Advances in identification and selection of personalized neoantigen/T-cell pairs for autologous adoptive T cell therapies[J]. Oncoimmunology, 2021, 10(1): 1869389. doi: 10.1080/2162402X.2020.1869389
[60] Orlando D, Miele E, De Angelis B, et al. Adoptive Immunotherapy Using PRAME-Specific T Cells in Medulloblastoma[J]. Cancer Res, 2018, 78(12): 3337-3349. doi: 10.1158/0008-5472.CAN-17-3140
[61] 成丁财, 王睿昊, 昂小杰, 等. 基于单细胞测序筛选转移性前列腺癌靶基因[J]. 临床泌尿外科杂志, 2021, 36(8): 643-652. https://lcmw.chinajournal.net.cn/WKC/WebPublication/paperDigest.aspx?paperID=eafb0d6f-ba5d-45b7-9f37-5ff83ded5c6a
-
计量
- 文章访问数: 1723
- PDF下载数: 888
- 施引文献: 0
下载: